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Human influenza A viruses have been the cause of enormous socio-economic losses
worldwide. In order to combat such a notorious pathogen, hemagglutinin protein (HA)
has been a preferred target for generation of neutralizing-antibodies as potent therapeu-
tic/diagnostic agents. In the present study, recombinant anti-HA single chain variable
fragment antibodies were constructed using the phage-display technology to aid in
diagnosis and treatment of human influenza A virus infections. Spleen cells of mice
hyper-immunized with A/New Caledonia/20/99 (H1N1) virus were used as the source for
recombinant antibody (rAb) production. The antigen-binding phages were quantified after
six rounds of bio-panning against A/New Caledonia/20/99 (H1N1), A/California/07/2009
(H1N1)-like, or A/Udorn/307/72(H3N2) viruses. The maximum phage yield was for the
A/New Caledonia/20/99 (H1N1), however, considerable cross-reactivity was observed for
the other virus strains as well. The HA-specific polyclonal rAb preparation was subjected
to selection of single clones for identification of high reactive relatively conserved epitopes.
The high-affinity rAbs were tested against certain known conserved HA epitopes by
peptide ELISA. Three recombinant mAbs showed reactivity with both the H1N1 strains
and one (C5) showed binding with all the three viral strains. The C5 antibody was thus
used for development of an ELISA test for diagnosis of influenza virus infection. Based
on the sample size in the current analysis, the ELISA test demonstrated 83.9% sensitivity
and 100% specificity. Thus, the ELISA, developed in our study, may prove as a cheaper
alternative to the presently used real time RT–PCR test for detection of human influenza
A viruses in clinical specimens, which will be beneficial, especially in the developing
countries.
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Introduction
Flu is a respiratory illness, caused by influenza virus, with annual global attack rate of 5–10% in adults
and 20–30% in children, causing significant levels of illness, hospitalization, and death (1). Influenza
virus is anRNAviruswith immunogenic surface receptors, hemagglutinin (HA), and neuraminidase
(NA). Error-prone RNA dependent RNA polymerase (2) and segmented genome enable influenza
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viruses to undergo antigenic shifts (major) and antigenic drifts
(minor), which cause changes in the surface glycoproteins, HA
and NA, and permit the virus to evade the adaptive immune
response of the host cells. Such phenomena back the threat posed
by influenza viruses for occurrence of frequent epidemics and
pandemics (3), in spite of the available antivirals for treatment
(4) or the vaccines for prevention and control of the disease
(5). In view of such emerging and re-emerging outbreaks, timely
diagnosis of the influenza virus infections in humans is essential.
The developing countries, where limited resources are available,
are in urgent requirement of alternate strategies to the expensive
molecular real time RT–PCR test (6), which is currently used
for diagnosis of flu. The cheaper alternative could highly mini-
mize the loss of resources caused by frequent occurrence of the
influenza virus infections. In the wake of such an issue, the present
study was undertaken to develop recombinant antibodies (rAbs)
against the HA antigen of human influenza A virus by phage-
display technique for their subsequent use in diagnosis and/or
therapy. Antibodies play important role in the course of natural
protection against influenza virus infections; theHAantigen being
the major target (7, 8).
Monoclonal antibodies (mAbs), since their advent in 1975 by
Kohler and Milstein, using hybridoma technology, have proved
to be potential diagnostic molecules (9–11). However, due to the
well-known limitations of the conventional hybridoma technique,
development of recombinant monoclonal antibodies (rAbs) by
newer and more efficient molecular methods is preferred. Such
rAbs have contributed immensely in medical and pharmaceutical
research, cancer therapy, and diagnosis and treatment of infec-
tious diseases (12–15). A major advancement in the production
of rAbs has been the invention of phage-display technology, where
high affinity and high specificity antibodies can be developed (16)
against the antigen of interest.
In the present study, we developed recombinant single chain
variable fragment (scFv) antibodies against the HA antigen of
A/New Caledonea/20/99 (H1N1) virus. Anti-HA influenza mAbs
have been developed for various applications, however, most
of them are either hybridoma-based (17–20) or against HPAI
H5N1 viruses (21, 22). The anti-HA rAbs produced in the current
work showed cross-reactivity against the A/California/07/2009
(H1N1)-like or/Udorn/307/72(H3N2) viruses and helped in the
development of a diagnostic ELISA test with 83.9% sensitivity
and 100% specificity. The therapeutic efficacy of the one hetero-
subtypic rAb (C5) is being evaluated in our laboratory, which
has shown promising results so far (data not shown). Further
assessment of the anti-HA influenza rAb developed in the present
work would help to validate its efficiency as potential diagnostic
and therapeutic agent.
Materials and Methods
Hyperimmunization of Mice
Five 6–11weeks old Balb/c mice were immunized via intra-
muscular route with 1:128 HA titer of influenza A/New Cale-
donia/20/99(H1N1) virus, in a final volume of 100μl, made
up with 1 PBS (23). The virus administration was done on
20th, 35th, 42nd, and 51st days post first immunization. A day
before each immunization, themice sera were collected and tested
for detection of anti-HA antibodies by indirect Enzyme Linked
Immunosorbent Assay (ELISA) against the HA antigen of the
influenza A/New Caledonia/20/99 (H1N1) virus. Permission for
animal experiments was obtained by the Institutional Animal
Ethics Committee (IAEC), which is registered under Committee
for the Purpose of Control and Supervision of Experiments on
Animals (CPCSEA), Government of India.
Indirect ELISA
The HA antigen of influenza A/New Caledonia/20/99(H1N1)
virus diluted in NaHCO3 coating buffer pH 9.6 was coated onto
ELISA wells by incubation at 4°C for overnight. The wells were
washed twice with PBST (1 PBS containing 0.5% Tween 20),
and blocked with 1% BSA in PBS for 1 h at room temperature
(RT). The wells were washed four times with PBST and then
incubated with different dilutions of the immunized mice sera as
primary antibody at RT for 2 h. The wells were washed vigorously
with 1 PBST five times and incubated with HRP-conjugated
rabbit anti-mouse antibody (1:1000 dilution in PBS) at RT for
1 h 30min. The unbound secondary antibody was removed from
the wells by 5–7 washings with PBST followed by addition of
50μl of the TMB substrate solution and incubation for 25min
at RT. The reaction was stopped by the addition of 1M sul-
furic acid and the absorbance was measured at 450 nm in the
ELISA reader (ELX800MS, Biotek Instruments, Inc., Winooski,
VT, USA).
Collection of Spleen and Preparation of cDNA
Template
After establishment of sufficient immune response against the
virus strain, on 53th day, two of the fivemice were given intranasal
instillation with influenza A/New Caledonia/20/99 (H1N1) virus,
followed by aseptic dissection on the 55th day for collection of
spleen. Following RBC lysis, the spleen cells were re-suspended
in 1ml of RPMI medium and subjected to live cell count estima-
tion using Neubauer’s Hemocytometer. Aliquots of approximately
3.5 106 cells were made and re-suspended in five volumes of
RNAlater (Sigma-Aldrich). After overnight incubation at 4°C, one
aliquot of the cell suspension was subjected to total cellular RNA
isolation using RNeasy Mini Kit (Qiagen) and thereafter total
mRNA isolation using the Oligotex mRNA Mini Kit (Qiagen) as
per the manufacturer’s instructions. Synthesis of cDNA was done
using M-MuLV Reverse transcriptase enzyme. The reaction mix
(final volume of 25μl) consisted of 10μl of the isolated mRNA,
800μM dNTP mix, 200U of M-MuLV enzyme, 0.2μl RNase
inhibitor, 2μl oligo-dT primer, and 1 M-MuLV RT buffer. The
reaction was set-up at 42°C for 2 h followed by heat inactivation
of enzyme at 94°C for 5min.
Amplification and Cloning of scFv Gene
Repertoire
The variable light (VL) and variable heavy chain (VH) genes were
amplified from the cDNA using degenerate mouse IgG primer set
(Cat. No. F2010, Progen Biotechnik, GmBH, Germany), consist-
ing of 11 degenerate forward primers for either VH chain gene or
VL chain gene amplification. Initially, a 10μl reaction mix was
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set-up using primer set I. The reaction consisted of 2.5μMof each
primer, 1 PCR buffer, 2.5U of Hot Star TaqDNA polymerase
(Qiagen), 0.5mM of the dNTP mix, 2μl of cDNA, and 2mM of
MgCl2. Initial denaturation was carried out at 94°C for 15min
followed by 35 cycles of denaturation (94°C for 30 s), annealing
(55°C for 30 s), and extension (72°C for 30 s), and a final extension
at 72°C for 10min. The reaction was finally held at 4°C and
the PCR products were resolved on 1.5% agarose gel. Second
set of PCR reactions were carried out, using the corresponding
Set-II forward primers, which showed amplification in the Set-I
reaction. The second set of PCRwas performed for introduction of
restriction sitesNcoI (50) andHindIII (30) to the amplifiedVH gene
fragments and MluI (50) and NotI (30) to the amplified VL gene
products. The Set-II reactions were put up as described for the
Set-I. After analysis on the agarose gel, DNA bands from positive
PCR reactions were purified and pooled for cloning in the pSEX81
phagemid vector.
The purified VL gene pool was digested with MluI and NotI
restriction enzymes (Fermentas) in appropriate buffer and ligated
into 50 ng of the digested pSEX81 vector at 1:3 vector: insertmolar
ratio using 0.4 Weiss Units of T4 DNA ligase at 4°C overnight
incubation. The ligated products were transformed into ultra-
competent cells XL1-Blue strain of E. coli and plated onto ampi-
cillin (100μg/ml) supplemented nutrient agar plates followed by
overnight incubation at 37°C. The colonies obtained over the
agar plates were scraped and propagated in LB/amp (100μg/ml)
medium and subjected to phagemid isolation for restriction anal-
ysis with MluI and NotI REs, for confirmation of the VL gene
cloning in the vector.
The pSEX81-VL vector was further digested with HindIII and
NcoI R.E.s (Fermentas) in appropriate buffer and insertion of the
RE digested pooled VH gene DNA at 1:3 vector: insert molar
ligation ratio using 0.4 Weiss Units of T4 DNA ligase in an
overnight reaction at 4°C. The ligation mix was transformed and
the resulting colonies were scraped and propagated for restriction
analysis by NcoI and NotI REs to confirm the cloning of the
complete scFv cassette in the pSEX81 vector.
Construction of Mouse Recombinant
Phage-scFv Library
Phage Rescue
The pSEX81-scFv transformed E. coli XL1-Blue cells were grown
overnight in 10ml SOB–GATmedium (SOB broth supplemented
with 100mM glucose, 100μg/ml ampicillin and 10μg/ml tetra-
cycline) at 37°C with shaking at 200 rpm. The overnight culture
was inoculated at 1:100 dilution in SOB–GAT medium, incu-
bated at 37°C with shaking at 180 rpm and monitored every
hour for bacterial growth till an OD600 of 0.3 was obtained. The
lyophilized hyperphage M13K07ΔPIII (Progen Biotechnik Cat.
No. PRHYPE) was re-constituted in 2ml of the autoclaved milliQ
water just before use, as per the manufacturer’s instructions and
added to the log phase cells at an MOI of 20 (Multiplicity of
Infection) representing the average number of phages per bacteria
was calculated by using the following formula:
MOI = No. of phage (ml added  plaque forming units/ml)No. of bacteria added
The hyperphage-infected culture was incubated at 37°C with-
out shaking for 30min and then shaking at 260 rpm for 30–45min.
The cells were harvested by centrifugation at 3,000 rpm for
10min at RT and re-suspended in equal volume of pre-warmed
SOB–AKT medium (SOB broth supplemented with 100μg/ml
ampicillin, 50μg/ml kanamycin and 10μg/ml tetracycline). The
cultures were incubated overnight at 34°C with shaking at
220 rpm (24).
Phage Precipitation
The overnight culture was centrifuged at 3,000 rpm for 15min
at room temperature and the supernatant transferred in a fresh
tube. The phage particles in the supernatant were precipitated by
addition of one-fifth volume of 20% PEG, 2.5M NaCl and incu-
bating on ice for 1 h, followed by centrifugation at 4,000 rpm/4°C
for 40min. The pellet was re-suspended in phage dilution buffer
(10mM Tris–HCl pH 7.5, 20mMNaCl, 2mM EDTA) and stored
at 4°C until further use (24).
Phage Quantification ELISA
For optimization, two-fold dilutions of the rescued phages were
prepared in coating buffer (sodium bicarbonate buffer pH 9.6),
coated onto ELISA wells in duplicate and incubated at 4°C
overnight. After incubation at 37°C for 15–20min, the wells were
washed thrice with PBS and blocked for 1½h with 2% skimmed
milk in PBS (SMP) at room temperature. The wells were washed
three times with PBS followed by addition of different dilutions
of anti-M13 mouse monoclonal antibody B62-FE2 against PVIII
coat protein of the M13 phage. After 1½ h incubation, the wells
were washed three times with PBS and incubated with anti-
mouse-HRP conjugated antibody (SIGMA, affinity purified anti-
body) 1:1000 diluted in SMP, for 1 h, followed by washing with
PBS with 1–2min hold per wash and incubation with 50μl of sub-
strate solution (5mg OPD, 4μl H2O2 in phosphate-citrate buffer)
at 37°C for 15min. The absorbance was measured at 492 nm;
referencewavelength being 620 nm (MagellanV 7.1). All the incu-
bation steps were done at RT unless individually mentioned (25).
Bio-Panning
Bio-panning was optimized using protocols which differed in the
choice of surface area, and type of elution buffer. The surface
area tested included 96-well microtiter plate, immunotube and
six-well tissue culture plate, while the elution buffers included
0.1M HCl (adjusted to pH 2.2 with glycine), trypsin (1, 2, and
5μg/ml) and 100mM triethylamine (pH 11.0).The optimized
procedure, finally preferred for selection of HA-specific recom-
binant phages is as follows. A MaxiSorp Immuno Tube (Nunc,
Thermo Fisher Scientific, USA) was coated with influenza A/New
Caledonia/20/99 virus (1:128 HA titer) diluted in a total volume
of 4ml coating buffer [0.2M Na2CO3NaHCO3 (pH 9.6)], and
kept at 4°C overnight followed by washing with PBS and then
incubationwith blocking solution (2% SMP) at 37°C/1 h. The tube
waswashed thricewith PBS and incubatedwith the rescued phage,
vol 1ml, at room temperature for 1 h with shaking at 35 rpm
and then without shaking for 45min. After washing 10 times
each with PBST (PBS with 0.1% Tween 20) and PBS, the antigen-
specific phage particles were eluted by incubation with 1ml of
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100mM triethylamine (Sigma) for maximum 10min. The eluted
phage was aspirated into a tube containing 0.5ml of Tris–HCl
pH 7.5, for neutralization of the eluted phage (26). The panning
procedure was repeated six times for selection of HA-specific scFv
antibody-phages with stringency of washing increased for each
round. Total phage yield (in triplicates) was assessed after each
round of bio-panning by ELISA.
Assessment of Cross-Reactivity
The phages precipitated after the last two rounds of bio-panning
were also assessed (in duplicates) for reactivity against the
A/California/07/2009 (H1N1)-like or A/Udorn/307/72(H3N2)
viruses. After the sixth round of bio-panning, 56 phage clones
were randomly selected and underwent small-scale phage rescue
as previously described (24). The precipitated phage preparations
from individual clones were tested for binding activity against
HA of influenza A/New Caledonia/20/99 virus. The clones
showing high reactivity were further analyzed for cross-reactivity
against HA antigens of A/California/07/2009 (H1N1)-like
or/Udorn/307/72(H3N2) viruses by phage ELISA as previously
described (25). Briefly, of HA of each of the virus diluted in
coating buffer were applied to ELISA plate wells and incubated
overnight at 4°C. The wells were washed twice with 1 PBS and
blocked with 2% SMP (2% skim milk powder in PBS) for 2 h
at RT. HA-specific precipitated recombinant phage preparation
(1:2 diluted in 2% SMP) was added to each well and incubated at
RT for 1 h. After washing six times with 400μl PBS per well, the
bound phage were detected with the anti-M13 antibody B62-FE2
against PVIII coat protein of the M13 phage.
Peptide ELISA
Five peptides (27) were commercially synthesized and used for
testing the phage-scFv antibodies for analysis of the epitopes
identified by them by peptide ELISA. The peptide sequences
were chosen based on the previous report that these were lin-
ear HA epitopes and relatively conserved among different sub-
types of influenza A viruses. The peptides (about 2μg/well) in a
final volume of 50μl coating buffer (Na2CO3Na2HCO3, pH 9.6)
were coated onto ELISA wells and incubated overnight at 4°C.
The wells were washed with PBST (1 PBS with 0.1% Tween 20)
once, followed by threewasheswith PBS. Thewells were incubated
with blocking buffer (1% BSA in 1 PBS) at 37°C for 1 h. After
washing, selected phage-bound scFv was applied onto each well.
After incubation at 37°C for 2 h, the wells were washed with
washing buffer (1M NaCl, 0.05% Tween 20) for four times, and
incubated with anti-mouse HRP conjugated antibody (1:1000) for
1 h followed by one washing with PBST and three washings with
PBS and detectionwith substrate, and absorbancemeasurement at
490 nm in ELISA reader. Sequences of the peptides tested against
the scFv antibodies are mentioned in Table 1.
ELISA for Diagnosis of Influenza A Virus Infection
A total of 53 human nasal/throat swab specimens were tested for
development of the phage-scFv antibody-based diagnostic ELISA
test. The samples were collected from various hospitals in Delhi,
India and were already tested with the standard real time RT–PCR
test. A total of 53 samples were tested. Forty-seven samples were
TABLE 1 | Sequences of the peptides tested against the scFv antibodies.
Peptide Position Sequence
P1 38–52 EKNVTVTHSVNLLED
P2 58–72 LCKLRGVAPLHLGKC
P3 318–332 GKCPKYVKSTKLRLA
P4 318–332 GACPRYVKSNTLKLA
P5 318–332 GECPKYVRSAKLRMV
frompatients, who acquired natural infection of influenzaA virus,
of which 10 patients were diagnosed for pH1N1/09 virus infection
and 37 for seasonal influenza A virus (14 H1N1+ 23 H3N2)
infection by real time RT–PCR. Six individuals served as healthy
controls that did not encounter any influenza virus infection since
more than 6months from the date of sample collection, and were
also real time RT–PCR negative for the viral infection.
The ELISAwells were coatedwith 1:2 diluted clinical specimens
in coating buffer overnight at 4°C, followed by washing with PBST
(1 PBS with 0.05% Tween20) and PBS. The wells were blocked
with 2% skimmedmilk in PBST for 1 h at 37°C and incubatedwith
C5 phage-scFv antibody at 37°C for 2 h. The wells were washed
with PBST andPBS followed by detectionwith the anti-M13phage
antibody B62-FE2 against PVIII coat protein of the M13 phage
as described before. Following the addition of TMB substrate, the
reaction was stopped and the absorbance wasmeasured at 450 nm
in an ELISA plate reader. Each sample was tested in duplicate and
the maximum absorbance was measured by using the P3 peptide
in place of the test samples. The samples from healthy controls
served as negative controls for the test. The sensitivity and speci-
ficity of the test (26) were calculated by the following formulae,
where determination of the true positive or true negative samples
was done by real time RT–PCR analysis.
Sensitivity = [True positive divided by sum of true positive and
false negative] 100
Specificity = [True negative divided by sum of true negative and
false positive] 100
Results were expressed as sensitivity and specificity of the test
in comparison to real time RT–PCR test for diagnosis of influenza
A virus infection.
Results
A total of 6- to -11-week-old Balb/c mice were immunized via
intra-muscular route with pandemic influenza A H1N1 (2009)
virus. A relatively high immune response was observed after
booster doses of pandemic influenza A H1N1 (2009) virus as
confirmed by ELISA with immunized mice sera. The absorbance
measured for the anti-HA antibodies before the first virus admin-
istration was 0.620, before fifth immunization dose was 3.129
(Table 2) and exceeded the detectable range post 48 h of the
fifth immunization. The increase in the antibody titer upon each
immunization is represented in the Figure 1.
Amplification and Cloning of the Antibody Genes
After achieving a considerable antibody titer against the HA anti-
gen, spleen was collected from two of the hyper-immunized mice.
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TABLE 2 | Absorbance values observed in ELISA for estimation of anti-HA
antibodies in mice sera, after each immunization with influenza A/New
Caledonia/20/99(H1N1) virus.
S.No. Day OD450
1 1 0.620
2 20 1.507
3 35 2.214
4 42 2.956
5 51 3.129
FIGURE 1 | Graphical representation of the mean antibody titers in
sera of immunized mice before each immunization. High anti-HA
antibody levels were detected in the hyper-immunized animals after 51 days of
the immunization schedule.
A total of 7.5 106 viable B cells were obtained after preparation
of single cell suspension of hyper-immunizedmice’s spleen. Three
and a half million B cells were used for total RNA isolation.
One microgram of the mRNA, which was isolated from the total
cellular RNA, was subjected to synthesis of cDNA to be utilized as
template for amplification of the antibody genes. The VL and VH
genes were individually amplified using a commercially available
mouse IgGprimer set. DNAbands at expected sizes (asmentioned
in the manufacturer’s protocol) of 400 bp for VH and ~380 bp for
VL were observed in 10 out of 11 degenerate forward primers
for VH gene DNA and 9 out of 11 primers for VL gene DNA
(Figure 2). All the amplicons of VL and VH gene were individually
purified from the gel. First, the VL gene pool was cloned in the
pSEX81 phagemid vector followed by cloning of the VH gene pool.
Digestion with the restriction enzymes flanking the scFv cassette
(NcoI and NotI) confirmed the insertion of both the genes and
thus cloning of the complete scFv pool in the phagemid vector
(Figure 3).
Phage Rescue
The scFv displaying recombinant phages were rescued from
pSEX81-scFv transformed E. coli XL1-Blue cells after infection
with the hyperphage (M13K07ΔPIII). After overnight incubation
at 34°C/220 rpm, the culture showed uniform turbidity. Differ-
ent dilutions of the precipitated phage preparation were titrated
against various dilutions of the tracing antibody for optimization.
A dilution of 1:2 of the rescued phage and 1:200 of the tracing
antibody were found optimum for detection of the recombinant
phages in ELISA.
The HA-specific recombinant phages were selected by the bio-
panning procedure. The phage yield was observed to show a
marked increase after the sixth round of bio-panning (Figure 4)
against the influenza A/New Caledonia/20/99 virus strain.
Cross-Reactivity and Peptide ELISA
The influenza A/New Caledonia/20/99-bio-panned phage prepa-
ration was tested against the pandemic H1N1/09 and seasonal
H3N2 viruses, after fifth and sixth rounds of bio-panning and
it was observed that there was no considerable increase in the
total phage yield against the non-specific viral strains, although
the reactivity levels of the recombinant scFv-phage preparation,
after the fifth round, were similar against the two H1 sub-types
(Figure 5). Of the 56 clones, five (A11, C5, C8, E9 and G6)
showed high reactivity against the A/New Caledonia/20/99 (data
not shown). Of these five scFv clones, three clones (A11, C5 and
E9) cross-reacted well with A/California/07/2009 (H1N1)-like
virus, and one (C5) cross-reacted with A/Udorn/307/72(H3N2)
virus (Figure 6).The high reactivity rAb clones were further ana-
lyzed by peptide ELISA. The identification of the epitopes, being
recognized by the scFv clones was done against the previously
characterized peptides (27). The phage-scFv antibodies, A11, C8
andG6, did not bind to any of the peptides tested, while C5 and E9
showed binding activities with the peptide P2, and C5 phage-scFv
antibody showed variable binding activities with three peptides
P3, P4, and P5 (Figure 7). The peptide P1 was not recognized by
any of the two phage-scFv anti-HA rAbs.
ELISA for Diagnosis of Influenza A Virus Infection
The ELISA test was developed using the C5 phage-scFv anti-
body, as it was found to react with all the three HA, i.e., sea-
sonal H1, pandemic H1, and H3 antigens. The peptide P3 was
taken as the positive control and as a measure of maximum
absorbance. Themean absorbance value of the negative specimens
was taken as cut-off to determine the sample positivity. Among
the 47 true positive specimens, the rAb-based ELISA test detected
influenza A virus in 38 samples, while all the six true negative
controls were observed to be negative by the ELISA test. Thus, the
ELISA test developed herein showed 83.9% sensitivity and 100%
specificity.
Discussion
Influenza A viruses pose considerable economic burden both on
the society and individuals in terms of consumption of health
care resources and lost productivity. The occurrence of frequent
flu outbreaks leads to large-scale socio-economic losses and calls
for improvement in the production of reagents, in terms of large
scale production, uniform quality, low cost, and stability for effec-
tive diagnosis and management of the disease. With the advent
of upgraded technologies, rAbs have provided great advantages
against the conventional monoclonal antibodies (28, 29). Once
developed, rAbs are economically one of the most feasible diag-
nostic and therapeutic agents and allow mass scale production. A
rAb can be developed by various procedures, for e.g., by conven-
tional recombinant expression in prokaryotic expression system
or by recombinant methods, such as, phage-display technology.
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Heavy chain gene amplificationA
B Light chain gene amplification
VH gene amplicon
(400 bp)
400 bp
1        2        3       4       5        6      7       8       9     10      11     12 Lane 1-11: PCR products of
forward primers (1A-1L) 
Lane 12: 100bp DNA ladder
1        2        3       4       5        6       7       8       9     10      11 12
400 bp
Lane 1-11: PCR products of 
forward primers (1N-1W, 1Z)
Lane 12: 100bp DNA ladder
VL gene amplicon
(~ 380 bp)
FIGURE 2 | Amplified light chain DNA (~380bp) (B) and heavy chain DNA (400bp) (A) using mouse IgG library primer set. Lanes 1–11 represent PCR
products from 11 different degenerate forward primers supplied with the kit.
scFv cassette drop-out
(750 bp)
1000bp
R.E. digested pSEX81 
vector
1     2       3
Lane: Sample
1: 1 Kb DNA ladder 
2:  Undig. dsRF M13 phage DNA
3: R.E. dig. dsRF M13 phage DNA
FIGURE 3 | Cloning of the complete scFv cassette in the pSEX81 phagemid vector. The phage-display library of the murine scFv gene pool was constructed
by insertion of the antibody light and heavy chain gene DNA into the phagemid pSEX81 vector. Lane 3 represents the drop-out of the scFv DNA upon restriction
digestion with the restriction enzymes, NcoI and NotI, flanking the scFv cassette.
Phage-display technology is a powerful technique (30), which
allows easier and faster production of antibodies. The resulting
molecules exhibit high antigen specificity and can be produced
in large quantities, thus avoiding the use of conventional time-
consuming methods like hybridoma technology. Therefore, in
the present study, we aimed toward development of a recombi-
nant antibody-based economical test for a cheaper yet effective
diagnosis of human influenza A virus infection.
An antibody-phage-display library was constructed from B
cells of Balb/c mice hyper-immunized with pandemic influenza
A H1N1 (2009) virus. The VH and VL chain genes were
amplified using commercially available degenerate primer sets.
The sequences of the mouse IgG library primers were finalized
after analysis of the various antibody sequences available in the
Kabat-Wu data book (31), so as to enable amplification of asmuch
possible antibody variable regions. Since, the desired template
sequences were not known; similar sequences were grouped for
choosing putative primer sequences from each group, which were
then compared against all database sequences for selection of
best-fitting primer sequences. The process was repeated until all
the database sequences were covered (31).
In order to diminish a bias against particular sequences, the
amplification of VH and VL genes was done by two polymerase
chain reactions using two separate mouse IgG library primer
sets. The first set provided an unbiased amplification, while the
second set was necessary for introduction of restriction endonu-
cleases sites to allow cloning of the amplified immunoglobulin
gene fragments into pSEX81 phagemid vector. The recognition
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FIGURE 4 | Affinity selection of phage-bound anti-HA scFv antibodies
from the antibody library. A considerable rise in the specific scFv
antibodies was observed after the sixth round of bio-panning against the
A/New Caledonia/20/99(H1N1) virus.
FIGURE 5 | Binding activity of the polyclonal rAb preparation against
the three viral strains. The total phage yield after the last two rounds of
bio-panning was analyzed against the A/New Caledonia/20/99(H1N1),
A/California/07/2009(H1N1)-like and A/Udorn/307/72(H3N2) viruses by
ELISA.
FIGURE 6 | Assessment of cross-reactivity of the relatively high affinity
anti-HA (A/New Caledonia/20/99(H1N1) virus) monoclonal rAbs
against the other influenza A virus sub-types, A/California/07/2009
(H1N1)-like and A/Udorn/307/72(H3N2) viruses. The ELISA absorbance
value for each of the cross-reactive strains was divided by that of the specific
strain and multiplied by 100 to generate the percent cross-reactivity.
sequences of NcoI (50) and HindIII (30) were added to the ampli-
fied heavy chain gene fragments and MluI (50) and NotI (30) to
the amplified light chain gene fragments. The choice of restriction
enzymes was based on various advantages offered by them, viz.
FIGURE 7 | Peptide ELISA. Different peptide sequences (representing linear
HA epitopes) were synthesized and tested against the monoclonal
phage-display antibodies for analysis of the binding activity. The C5 antibody,
which was found to react with all the four HA peptides was used for
development of the diagnostic ELISA test.
(i) low probability to cut within mouse VH or VL coding regions,
(ii) optimal cloning efficiency by production of overlaps of four
nucleotides or more, (iii) methylation independence, and (iv)
more than 90% efficiency in double digestion reactions (32).
DNA bands at expected sizes of ~400 and ~380 bp were
observed after PCR amplification of VH and VL genes, respec-
tively, which were individually purified for cloning in pSEX81
phagemid vector. The complete scFv cassette (750 bp) containing
phagemid clones were transformed in E. coli XL1-Blue cells and
subjected to rescue of recombinant phages expressing the pIII-
scFv fusion proteins on their surface. The rescued phage antibody
librarywas subjected to selection of the anti-HAantibodies by bio-
panning, which is an affinity-based selection process. The anti-
body with the desired specificity is selected from a recombinant
heterogeneous antibody repertoire and enriched over a million
fold by selection against the specific antigen (33). The rescued
phages were quantified after each round of bio-panning and a
marked increase was observed after sixth round of bio-panning.
The recombinant scFv-displaying phage preparations, bio-panned
against the influenza A/Caledonia/20/99 virus, were analyzed
for cross-reactivity after fifth and sixth rounds against the
A/California/07/2009 (H1N1)-like or A/Udorn/307/72(H3N2)
viruses. We observed that the recombinant phages reacted to
similar levels against theH1N1 strains, after the fifth round of bio-
panning. However, after the sixth round of the affinity selection,
an insignificant increase in the phage yield was observed against
the pH1N1/2009 virus. The percentage of cross-reactivity of the
recombinant phages for the H3N2 strain of the virus was very
low (~40%), which can be explained by the dissimilarity of the
H3 from the H1 sub-type. We chose to continue our study with
the phage-bound antibodies, as the conversion of scFv-phage
antibody to its soluble form leads to alteration in the antibody
specificity (34). Further analysis of the single phage-scFv clones
showed that six clones had relatively high reactivity against the
specific influenza virus sub-type (A/Caledonia/20/99 virus), of
which the six clones (A11, C5 and E9) and one clone (C5) showed
cross-reactivity with A/California/07/2009(H1N1)-like virus, and
A/Udorn/307/72(H3N2) virus respectively. Since, the clones were
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selected via a rigorous procedure of affinity selection and showed
cross-reactivity among the other HA sub-types, we attempted to
test the clones against some of the already validated conserved
linear epitopes (27). The C5 scFv-phage clone was found to react
with three different peptides corresponding to three different
HA sub-types, with variable reactivity, though. Therefore, the C5
scFv-phage antibody was employed to develop an ELISA test for
diagnosis of the human influenza A virus infection in clinical
specimens. The non-reactivity of the other three phage-scFv rAbs,
i.e., A11, C8, and G6 antibodies, may be due to their specificities
against the epitopes other than the ones tested in the experi-
ment. Moreover, in peptide ELISA, only linear epitopes could
be tested, therefore, it is likely that A11, C8, or G6 would be
specific against conformational epitopes. The most widely and
the recommended real time RT–PCR test imposes restriction
due to its high cost, however, the ELISA test proposed in the
current study may be performed in any laboratory with basic
facilities/manpower/expertise. The sample size tested in the cur-
rent study showed 83.9% sensitivity and 100% specificity for the
ELISA test, however, a higher sensitivity is crucial for application
of the test for detection of influenza A virus in the field spec-
imens. In this regard, the work is in progress in our laboratory
by testing of higher number of routinely collected human clinical
samples.
Conclusion
Presently, the real time RT–PCR test is the most widely used tech-
nique to diagnose flu (6). However, in the developing countries,
the high cost of such test poses limitations in better management
and efficient surveillance of the disease. Therefore, we attempted
to develop the diagnostic ELISA test as a low cost alternative for
the diagnosis of influenza virus infections. The number of samples
tested in the present study yielded 83.9% sensitivity and 100%
specificity of the test. However, further validation of the results
by testing a larger number of samples would be required, which
would further help in determination of the efficiency of the ELISA
test. Following such validation, the ELISA test developed by us
holds significance, as it can be used as an initial screening method
for the diagnosis of influenza virus infection in human specimens.
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